EMA says no new patients should be started on Esyma for uterine fibroids

EMA says no new patients should be started on Esyma for uterine fibroids

February 13 2018 Doctors should not initiate Esyma (ulipristal acetate) in women with uterine...

New warnings issued for pregnancy and women using valproate for epilepsy, migraine, or bipolar

New warnings issued for pregnancy and women using valproate for epilepsy, migraine, or bipolar

February 13 2018 The European Medicines Agency has issued new recommendations regarding use of...

EMA updates recommendations on avoidance of retinoids in pregnancy and effect on mental health

EMA updates recommendations on avoidance of retinoids in pregnancy and effect on mental health

February 12 2018 The European Medicines Agency has updated advice regarding the use of retinoids...

New Drug Safety Update issued on need for contraception with mycophenolate mofetil

New Drug Safety Update issued on need for contraception with mycophenolate mofetil

February 9 2018 The medicines regulator has issued a Drug Safety Update relating to mycophenolate...

Study flags up concerns over antibiotic resistance in children's E coli in urinary infections

Study flags up concerns over antibiotic resistance in children's E coli in urinary infections

February 8 2018 Antibiotic resistance in children’s E. coli is high against many...

  • EMA says no new patients should be started on Esyma for uterine fibroids

    EMA says no new patients should be started on Esyma for uterine fibroids

    Tuesday, 13 February 2018 12:18
  • New warnings issued for pregnancy and women using valproate for epilepsy, migraine, or bipolar

    New warnings issued for pregnancy and women using valproate for epilepsy, migraine, or bipolar

    Tuesday, 13 February 2018 12:11
  • EMA updates recommendations on avoidance of retinoids in pregnancy and effect on mental health

    EMA updates recommendations on avoidance of retinoids in pregnancy and effect on mental health

    Monday, 12 February 2018 14:21
  • New Drug Safety Update issued on need for contraception with mycophenolate mofetil

    New Drug Safety Update issued on need for contraception with mycophenolate mofetil

    Friday, 09 February 2018 15:01
  • Study flags up concerns over antibiotic resistance in children's E coli in urinary infections

    Study flags up concerns over antibiotic resistance in children's E coli in urinary infections

    Thursday, 08 February 2018 10:39

Umesh Modi is a chartered accountant, and Pamini Jatheeskumar is a chartered certified accountant at Silver Levene...
  Don Lavoie is alcohol programme manager at Public Health England and Gul Root is lead...
Don Lavoie is alcohol programme manager at Public Health England and Gul Root is lead pharmacist, Health and Wellbeing Directorate, Public Health England
More inWhite Papers  

handApril 27 2016

Methotrexate in combination with sulphasalazine and hydroxychloroquine has been found to be superior than oral methotrexate on its own for treating rheumatoid arthritis.

The effect of triple therapy was considered superior both in patients who have not had methotrexate before as well as those who have. In addition, triple therapy was considered equally effective to methotrexate plus any DMARD or tofacitinib for controlling disease activity, either as initial therapy or after an inadequate response to methotrexate.

With guidelines suggesting methotrexate be used in combination with biological disease modifying anti-rheumatic drugs (DMARDs), researchers are suggesting the ‘triple therapy’ combination of methotrexate, suphasalazine and hydroxychloroquine should be another valid option as it could be significantly cheaper than using methotrexate with biological DMARDs.

A meta-analysis looked at 158 trials covering data from more than 37,000 patients where methotrexate had been compared with any other DMARD or combination of DMARDs. There were number of trials where methotrexate in combination with other drugs - sulfasalazine and hydroxychloroquine (‘triple therapy’), biologics (abatacept, adalimumab, etanercept, infliximab, rituximab, tocilizumab), and tofacitinib (awaiting marketing authorisation in the EU) - was statistically superior to methotrexate on its own.

In addition, “triple therapy had statistically fewer withdrawals due to adverse events than methotrexate plus infliximab,” and “methotrexate plus abatacept had a statistically lower rate of withdrawals due to adverse events than several treatments.”

Methotrexate alone is considered as the first DMARD option for patients with rheumatoid arthritis. Guidelines then propose its use in combination with a biologic DMARD if the response to methotrexate is not adequate.

“Combining methotrexate with other conventional synthetic DMARDs, however, is more controversial,” said the authors. There should be “a therapeutic trial of triple therapy as initial treatment or after an inadequate response to methotrexate,” said the researchers in their study, published in the BMJ.

“As triple therapy costs 10-20 times less than biologic therapy and is not currently recommended strongly by international guidelines, this has important policy implications. Specifically, our results suggest that triple therapy should be considered as a low cost, effective treatment option either as initial treatment or after an inadequate response to methotrexate.”

Links:

GS Hazlewood. ‘Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying antirheumatic drugs for rheumatoid arthritis: abridged Cochrane systematic review and network meta-analysis’. BMJ 2016; 353: i1777 Published online April 212016 

Clinical News

  February 20 2018 A covert study of pharmacies has claimed that some pharmacies are failing to give adequate safety warnings when selling analgesics and cold remedies. The Consumer Association’s...
February 19 2018 Pharmacists should be receiving educational material this week on a new patient safety campaign from the Centre of Pharmacy Postgraduate Education. Resources have been mailed out ahead...